Merck & Co., Inc. (NYSE:MRK) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Merck from “hold” to “buy,” adding to a generally positive analyst backdrop. Overall, the stock now carries a “Moderate Buy” consensus with a target price of $128.18.
• Merck’s latest quarterly results beat expectations, with EPS of -$1.28 versus the expected -$1.47 and revenue of $16.29 billion topping estimates. Revenue also rose 4.9% year over year.
• The company continues to draw investor attention from both legal relief and pipeline momentum, including a >$50 million Gardasil settlement and ongoing strength in its oncology franchise, especially Keytruda.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also weighed in on MRK. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a research report on Monday, April 6th. Zacks Research raised Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $128.18.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $121.05 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The stock's 50 day moving average is $116.55 and its 200-day moving average is $112.39. The firm has a market capitalization of $298.96 billion, a price-to-earnings ratio of 34.10, a PEG ratio of 2.70 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the firm earned $2.22 earnings per share. Merck & Co., Inc.'s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Chesapeake Wealth Management grew its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock valued at $1,552,000 after purchasing an additional 87 shares during the period. South Plains Financial Inc. grew its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company's stock valued at $1,635,000 after purchasing an additional 89 shares during the period. Syverson Strege & Co grew its stake in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company's stock valued at $436,000 after purchasing an additional 90 shares during the period. Nations Financial Group Inc. IA ADV grew its stake in Merck & Co., Inc. by 0.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company's stock valued at $2,819,000 after purchasing an additional 91 shares during the period. Finally, Westside Investment Management Inc. grew its stake in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock valued at $331,000 after purchasing an additional 93 shares during the period. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reached a settlement of more than $50 million to resolve over 200 Gardasil-related lawsuits, removing a significant legal overhang and helping investors refocus on the company’s core business and pipeline. Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
• Positive Sentiment: Merck recently broke above both its 20-day and 50-day moving averages, a technical signal that traders often view as a sign of improving short-term momentum. Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
• Positive Sentiment: Merck’s oncology franchise continues to draw attention after ASCO 2026 updates highlighted Keytruda’s strength in solid tumors and other pipeline assets aimed at offsetting future exclusivity pressure. ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
• Positive Sentiment: Merck’s collaboration with Moderna on a personalized mRNA cancer vaccine also got a boost from positive long-term data disclosed by Moderna, reinforcing investor interest in the partnership. Why Is Moderna (MRNA) Stock Rocketing Higher Today
• Neutral Sentiment: Merck’s conference appearance and oncology strategy update likely kept investor focus on the pipeline, but the items available do not indicate a major new catalyst beyond ongoing progress. Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification - Slideshow

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.